[ibd-display-video id=449423 width=50 float=left autostart=true] This exclusive rating from Investor's Business Daily identifies share price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains tend to have an RS Rating of above 80 as they begin their biggest price moves.
Acceleron Pharma broke out earlier, but is now trading about 5% below the prior 38.06 entry from a cup with handle . In the case where a stock breaks out then falls 7% or more below the entry price, it's considered a failed breakout. If that happens, it's best to wait for a new pattern to form. Also keep in mind that the most recent pattern is a later-stage base, and such bases are more prone to failure.
Although earnings and sales growth came in at -30% and -4%, respectively, in the latest report, that marked acceleration for both earnings-per-share and sales.
The company earns the No. 215 rank among its peers in the Medical-Biomed/Biotech industry group. Celgene ( CELG ), Corcept Therapeutics ( CORT ) and Ligand Pharmaceuticals ( LGND ) are among the top 5 highly rated stocks within the group.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.